Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in moderate-to-severe COPD with type 2 inflammation
jRCT2080224762Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Dupilumab arm with Placebo arm (2 arms). Primary endpoint: Annualized rate of moderate or severe COPD exacerbations over 52 weeks. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2080224762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224762.